XML 47 R30.htm IDEA: XBRL DOCUMENT v3.25.0.1
Business Combination (Tables)
12 Months Ended
Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
Schedule of Total Purchase Price Consideration
The total purchase consideration was comprised of the following (in thousands):

Cash consideration for Antares shares outstanding as of May 24, 2022$956,886 
Consideration for Antares equity compensation awards(1)
45,828 
Consideration for seller transaction costs paid by Halozyme22,906 
Consideration related to Antares closing indebtedness settled by Halozyme19,683 
Cash consideration related to cash bonus awards paid by Halozyme
365 
Total purchase consideration
$1,045,668 
(1)    Consideration for Antares equity compensation awards consists of $32.2 million paid for vested equity awards as well as $13.6 million paid for the pre-combination portion of unvested equity awards that were accelerated as part of the Merger Agreement. The fair value of the unvested equity awards attributable to the post-combination period of $8.7 million is included in our consolidated statements of income during the year ended December 31, 2022.
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact our results of operations.
Amounts recognized as of 12/31/2023
Total purchase consideration, net of $46,548 cash acquired
$999,120 
Assets
Short-term investments498 
Accounts receivable, net81,960 
Inventories
28,068 
Prepaid expenses and other assets5,241 
Property and equipment, net28,661 
Intangibles, net589,800 
Liabilities
Accounts Payable7,197 
Accrued expenses43,692 
Deferred revenue, current portion2,509 
Deferred revenue, net of current portion1,207 
Deferred tax liabilities, net76,536 
Other long-term liabilities20,788 
Net assets acquired, excluding goodwill582,299 
Goodwill$416,821 
Schedule of Acquired Finite-Lived Intangible Assets by Major Class Useful lives and final values are presented in the table below.
Amount (in thousands)Useful life (years)
Auto-Injector technology platform$402,000 7
XYOSTED proprietary product136,200 10
TLANDO product rights2,900 10
ATRS-1902 (IPR&D)48,700 Indefinite
Fair value of intangible assets acquired$589,800 
Schedule of Acquired Indefinite-lived Intangible Assets by Major Class Useful lives and final values are presented in the table below.
Amount (in thousands)Useful life (years)
Auto-Injector technology platform$402,000 7
XYOSTED proprietary product136,200 10
TLANDO product rights2,900 10
ATRS-1902 (IPR&D)48,700 Indefinite
Fair value of intangible assets acquired$589,800 
Schedule of Business Acquisition, Pro Forma Information
The following unaudited pro forma financial information summarizes combined results of operations of Halozyme and Antares as if the companies had been combined as of the beginning of our fiscal year 2021 (in thousands).
Year Ended December 31,
2022
2021
Total revenues
$712,683 $627,292 
Net income218,723 295,634